Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target

Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):616-23. doi: 10.1007/s00259-008-1012-x. Epub 2008 Dec 18.

Abstract

Purpose: To analyse the influence of cancer-associated stroma on FDG-uptake in two carcinoma models characterized by different stromal degrees.

Methods: Eight nude mice were subcutaneously injected with DU-145 prostate cancer cells or BXPC-3 pancreatic cancer cells, and underwent FDG-PET imaging about 2 weeks after implantation. After the mice were killed, histology, and CD31 and GLUT1 immunohistochemistry were performed. To further evaluate the highly stromalized carcinoma using perfusion-sensitive imaging, four BXPC-3 tumours underwent two successive albumin-binding (MS-325) MRI scans during tumour growth.

Results: FDG uptake was significantly higher in the DU-145 than in the BXPC-3 tumours, which were hardly distinguishable from adjacent normal tissue. In the BXPC-3 tumours, histology confirmed the widespread presence of aberrant infiltrated stroma, embedded with numerous vessels marked by CD31. In both tumour types, the stromal matrix was negative for GLUT1. In DU-145 tumour cells, GLUT1 immunostaining was greater than in BXPC-3 tumour cells, but not homogeneously, since it was less evident in the tumour cells which were nearer to vessels and stroma. Finally, MS-325 MRI always clearly showed areas of enhancement in the BXPC-3 tumours.

Conclusion: Cancer-associated stroma has been reported to be capable of aerobic metabolism with low glucose consumption. Furthermore, it has been proposed that regions with high vascular perfusion exhibit a significantly lower FDG uptake, suggesting some vascular/metabolic reciprocity. Since our results are consistent with these recent findings, they signal a risk of tumour volume underestimation in radiotherapy if FDG uptake alone is used for target delineation of carcinomas, which suggests that additional evaluation should be performed using vasculature/perfusion-sensitive imaging.

MeSH terms

  • Animals
  • Carcinoma / diagnosis*
  • Carcinoma / diagnostic imaging
  • Cell Line, Tumor
  • Fluorodeoxyglucose F18 / pharmacology*
  • Glucose Transporter Type 1 / biosynthesis
  • Homozygote
  • Humans
  • Image Processing, Computer-Assisted
  • Immunohistochemistry / methods
  • Mice
  • Mice, Nude
  • Neoplasms / diagnosis*
  • Neoplasms / diagnostic imaging
  • Platelet Endothelial Cell Adhesion Molecule-1 / biosynthesis
  • Positron-Emission Tomography / methods*
  • Radiography
  • Radiopharmaceuticals / pharmacology*

Substances

  • Glucose Transporter Type 1
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Radiopharmaceuticals
  • Slc2a1 protein, mouse
  • Fluorodeoxyglucose F18